Protagenic Therapeutics, Inc. (PTIX)
Market Cap | 3.41M |
Revenue (ttm) | n/a |
Net Income (ttm) | -6.01M |
Shares Out | 4.45M |
EPS (ttm) | -1.37 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 53,711 |
Open | 0.880 |
Previous Close | 0.940 |
Day's Range | 0.760 - 0.925 |
52-Week Range | 0.680 - 2.220 |
Beta | 0.32 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Aug 12, 2024 |
About PTIX
Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
![](https://cdn.snapi.dev/images/v1/c/o/press10-2402708.jpg)
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion...
![](https://cdn.snapi.dev/images/v1/f/z/press14-2375758.jpg)
Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical ...
![](https://cdn.snapi.dev/images/v1/y/z/press4-2350593.jpg)
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Gen...
![](https://cdn.snapi.dev/images/v1/t/j/press7-2343853.jpg)
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mi...
![](https://cdn.snapi.dev/images/v1/a/i/conf4-2340746.jpg)
Protagenic Therapeutics Schedules First Q4 and FY 2023 Earnings Call
Call Scheduled for Monday, April 1st, 2024, at 4:30 pm ET NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, announced that the Co...
![](https://cdn.snapi.dev/images/v1/h/6/press3-2335170.jpg)
Protagenic Therapeutics Announces Resolution of Nasdaq Deficiency Notice
NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550(a)(2) as the closing bid pric...
![](https://cdn.snapi.dev/images/v1/s/1/press2-2273334.jpg)
Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
Company Anticipates Reporting Complete Phase I Single Dose Results in April NEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceutical innovator, ...
![](https://cdn.snapi.dev/images/v1/v/n/conf15-2102481.jpg)
Protagenic Therapeutics Announces Date of Annual Shareholder Meeting
NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, tod...
![](https://cdn.snapi.dev/images/v1/s/m/press3-2077751.jpg)
Protagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114
A potential major step toward treating stress-related neuro-psychiatric disorders NEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneering biop...
![](https://cdn.snapi.dev/images/v1/r/s/press3-1808288.jpg)
Protagenic Therapeutics to Effect 1-for-4 Reverse Stock Split
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price NEW YORK, NY / ACCESSWIRE / March 22, 2023 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX, the "Company") a biopharmaceuti...
![](https://cdn.snapi.dev/images/v1/o/3/conf4-1336320.jpg)
Protagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27th
NEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic di...
![](https://cdn.snapi.dev/images/v1/p/r/press16-1110955.jpg)
Protagenic Therapeutics Announces Third Quarter 2021 Results and Business Update
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...
![](https://cdn.snapi.dev/images/v1/p/r/press20-986293.jpg)
Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
Scientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and A ddiction to be discussed
![](https://cdn.snapi.dev/images/v1/p/r/press17-968764.jpg)
Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
NEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...
![](https://cdn.snapi.dev/images/v1/t/v/biotech12-924405.jpg)
Protagenic Therapeutics To Start Clinical Trials For Depression Candidate By 2021 End
Upon reviewing Protagenic Therapeutics Inc's (NASDAQ: PTIX) Investigational New Drug (IND) application for its lead compound, PT00114, the FDA has currently rejected the Company's IND. The application...
![](https://cdn.snapi.dev/images/v1/p/r/press10-923767.jpg)
Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
NEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...
![](https://cdn.snapi.dev/images/v1/p/r/press5-894840.jpg)
Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today...
![](https://cdn.snapi.dev/images/v1/c/o/conf14-870982.jpg)
Protagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
NEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic di...
![](https://cdn.snapi.dev/images/v1/p/r/press2-794949.jpg)
Protagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to Nasdaq
New York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a pu...
![](https://cdn.snapi.dev/images/v1/p/r/press6-785940.jpg)
Protagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public Offering
New York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a pu...